SEARCH:   Advanced

Blood, 1 September 2005, Vol. 106, No. 5, pp. 1867-1874. Prepublished online as a Blood First Edition Paper on May 12, 2005; DOI 10.1182/blood-2005-02-0468. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-02-0468v1 106/5/1867    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Flomenberg, N. Articles by Calandra, G. Search for Related Content PubMed PubMed Citation Articles by Flomenberg, N. Articles by Calandra, G. Related Collections Hematopoiesis and Stem Cells Transplantation Free Research Articles Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone Neal Flomenberg, Steven M. Devine, John F. DiPersio, Jane L. Liesveld, John M. McCarty, Scott D. Rowley, David H. Vesole, Karin Badel, and Gary Calandra From the Department of Medicine and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; the Department of Medicine and Siteman Cancer Center, Washington University, St Louis, MO; the Department of Medicine and James P. Wilmot Cancer Center, University of Rochester, Rochester, NY; the Department of Medicine and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA; the Adult Blood and Marrow Transplantation Program, Hackensack University Medical Center, Hackensack, NJ; the Medical College of Wisconsin, Milwaukee, WI; and AnorMED, Langley, BC, Canada. Hematopoietic progenitor cells (HPCs) traffic to and are retained in the marrow through the trophic effects of the chemokine stromal cell-derived factor-1 (SDF-1) binding to its receptor, CXC chemokine receptor 4 (CXCR4). AMD3100 reversibly inhibits SDF-1/CXCR4 binding, and AMD3100 administration mobilizes CD34+ cells into the circulation. We therefore tested the hypotheses that the combination of AMD3100 plus granulocyte colony-stimulating factor (G-CSF) (hereafter A + G) would be superior to G-CSF alone (hereafter G) in mobilizing hematopoietic progenitor cells (HPCs) and that A + G-mobilized cells would engraft as well as G-mobilized cells. The primary objective was to determine whether patients mobilized more progenitor cells per unit of blood volume of apheresis after A + G administration versus G alone. Secondary objectives were to determine whether patients mobilized with A + G compared with G alone required fewer apheresis procedures to reach the target level at least 5 x 106 CD34+ cells/kg for transplantation and to determine whether patients mobilized with A + G had at least a 90% success rate of autologous transplantation as assessed by neutrophil engraftment by day 21. Each patient served as his or her own control in a sequential mobilization design. All study objectives were met without significant toxicity. The results demonstrate that the combination of A + G is generally safe, effective, and superior to G alone for autologous HPC mobilization. (Blood. 2005;106:1867-1874) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Progenitor cell mobilization gets a boost from CXCR4 inhibition Susan F. Leitman Blood 2005 106: 1516-1517. [Full Text] [PDF] This article has been cited by other articles: A. Y. H. Leung and Y.-L. Kwong Haematopoietic stem cell transplantation: current concepts and novel therapeutic strategies Br. Med. Bull., November 8, 2009; (2009) ldp040v1. [Abstract] [Full Text] [PDF] J. F. DiPersio, I. N. Micallef, P. J. Stiff, B. J. Bolwell, R. T. Maziarz, E. Jacobsen, A. Nademanee, J. McCarty, G. Bridger, and G. Calandra Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma J. Clin. Oncol., October 1, 2009; 27(28): 4767 - 4773. [Abstract] [Full Text] [PDF] R. E. Donahue, P. Jin, A. C. Bonifacino, M. E. Metzger, J. Ren, E. Wang, and D. F. Stroncek Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures Blood, September 17, 2009; 114(12): 2530 - 2541. [Abstract] [Full Text] [PDF] A. K. Azab and I. M. Ghobrial Response: Sensitization initiated Blood, July 23, 2009; 114(4): 926 - 927. [Full Text] [PDF] Z. Zeng, Y. Xi Shi, I. J. Samudio, R.-Y. Wang, X. Ling, O. Frolova, M. Levis, J. B. Rubin, R. R. Negrin, E. H. Estey, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML Blood, June 11, 2009; 113(24): 6215 - 6224. [Abstract] [Full Text] [PDF] B. Nervi, P. Ramirez, M. P. Rettig, G. L. Uy, M. S. Holt, J. K. Ritchey, J. L. Prior, D. Piwnica-Worms, G. Bridger, T. J. Ley, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100 Blood, June 11, 2009; 113(24): 6206 - 6214. [Abstract] [Full Text] [PDF] A. K. Azab, J. M. Runnels, C. Pitsillides, A.-S. Moreau, F. Azab, X. Leleu, X. Jia, R. Wright, B. Ospina, A. L. Carlson, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy Blood, April 30, 2009; 113(18): 4341 - 4351. [Abstract] [Full Text] [PDF] M. A. Schroeder, M. P. Rettig, P. Ramirez, and J. F. DiPersio Optimal Mobilization of Normal and Leukemic Stem Cells via Modulation of Chemokine and Integrin Axes Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 15 - 22. [Full Text] [PDF] R. S. Y. Wong, V. Bodart, M. Metz, J. Labrecque, G. Bridger, and S. P. Fricker Comparison of the Potential Multiple Binding Modes of Bicyclam, Monocylam, and Noncyclam Small-Molecule CXC Chemokine Receptor 4 Inhibitors Mol. Pharmacol., December 1, 2008; 74(6): 1485 - 1495. [Abstract] [Full Text] [PDF] S. M. Devine, R. Vij, M. Rettig, L. Todt, K. McGlauchlen, N. Fisher, H. Devine, D. C. Link, G. Calandra, G. Bridger, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction Blood, August 15, 2008; 112(4): 990 - 998. [Abstract] [Full Text] [PDF] H. M. Lazarus, G. L. Phillips, R. H. Herzig, D. D. Hurd, S. N. Wolff, and G. P. Herzig High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later J. Clin. Oncol., May 10, 2008; 26(14): 2240 - 2243. [Full Text] [PDF] R. M. Lemoli and A. D'Addio Hematopoietic stem cell mobilization Haematologica, March 1, 2008; 93(3): 321 - 324. [Full Text] [PDF] A. Zernecke, I. Bot, Y. Djalali-Talab, E. Shagdarsuren, K. Bidzhekov, S. Meiler, R. Krohn, A. Schober, M. Sperandio, O. Soehnlein, et al. Protective Role of CXC Receptor 4/CXC Ligand 12 Unveils the Importance of Neutrophils in Atherosclerosis Circ. Res., February 1, 2008; 102(2): 209 - 217. [Abstract] [Full Text] [PDF] B. Lowenberg Acute Myeloid Leukemia: The Challenge of Capturing Disease Variety Hematology, January 1, 2008; 2008(1): 1 - 11. [Abstract] [Full Text] [PDF] E. F. Wolff, A. B. Wolff, Hongling Du, and H. S. Taylor Demonstration of Multipotent Stem Cells in the Adult Human Endometrium by In Vitro Chondrogenesis Reproductive Sciences, September 1, 2007; 14(6): 524 - 533. [Abstract] [PDF] M Devetten and J. Armitage Hematopoietic cell transplantation: progress and obstacles Ann. Onc., September 1, 2007; 18(9): 1450 - 1456. [Abstract] [Full Text] [PDF] A. C. Hirbe, J. Rubin, O. Uluckan, E. A. Morgan, M. C. Eagleton, J. L. Prior, D. Piwnica-Worms, and K. N. Weilbaecher Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone PNAS, August 28, 2007; 104(35): 14062 - 14067. [Abstract] [Full Text] [PDF] Y. Shiba, M. Takahashi, T. Yoshioka, N. Yajima, H. Morimoto, A. Izawa, H. Ise, K. Hatake, K. Motoyoshi, and U. Ikeda M-CSF Accelerates Neointimal Formation in the Early Phase After Vascular Injury in Mice: The Critical Role of the SDF-1-CXCR4 System Arterioscler Thromb Vasc Biol, February 1, 2007; 27(2): 283 - 289. [Abstract] [Full Text] [PDF] T. Kawai, U. Choi, L. Cardwell, S. S. DeRavin, N. Naumann, N. L. Whiting-Theobald, G. F. Linton, J. Moon, P. M. Murphy, and H. L. Malech WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4 Blood, January 1, 2007; 109(1): 78 - 84. [Abstract] [Full Text] [PDF] Z. Zeng, I. J. Samudio, M. Munsell, J. An, Z. Huang, E. Estey, M. Andreeff, and M. Konopleva Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias Mol. Cancer Ther., December 1, 2006; 5(12): 3113 - 3121. [Abstract] [Full Text] [PDF] A. F. Cashen, G. Calandra, R. MacFarland, S. Lopez, and J. F. DiPersio A Mobilizing Regimen of AMD3100 and G-CSF Increases Stem Cell Collection in Patients with Hodgkin's Disease, and PK Is Similar to That of Non-Cancer Patients. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 3053 - 3053. [Abstract] [PDF] A. Larochelle, A. Krouse, M. Metzger, D. Orlic, R. E. Donahue, S. Fricker, G. Bridger, C. E. Dunbar, and P. Hematti AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates Blood, May 1, 2006; 107(9): 3772 - 3778. [Abstract] [Full Text] [PDF] J. Chen, A. Larochelle, S. Fricker, G. Bridger, C. E. Dunbar, and J. L. Abkowitz Mobilization as a preparative regimen for hematopoietic stem cell transplantation Blood, May 1, 2006; 107(9): 3764 - 3771. [Abstract] [Full Text] [PDF] E. A. Copelan Hematopoietic stem-cell transplantation. N. Engl. J. Med., April 27, 2006; 354(17): 1813 - 1826. [Full Text] [PDF] S. M. Devine Antagonizing CXCR4 accelerates CD34+ cell mobilization Blood, December 1, 2005; 106(12): 3685 - 3686. [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020